JY
AQST icon

Jeff Yass’s Aquestive Therapeutics AQST Stock Holding History

Jeff Yass’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$535K Sell
128,505
-209,130
-62% -$880K ﹤0.01% 9768
2026
Q1 		$1.4M Sell
337,635
-249,614
-43% -$1.01M ﹤0.01% 7064
2025
Q4 		$3.79M Sell
587,249
-501,395
-46% -$3.12M ﹤0.01% 4491
2025
Q3 		$6.09M Buy
1,088,644
+621,883
+133% +$2.69M ﹤0.01% 3780
2025
Q2 		$1.54M Buy
466,761
+181,119
+63% +$520K ﹤0.01% 6366
2025
Q1 		$828K Buy
285,642
+91,768
+47% +$278K ﹤0.01% 7729
2024
Q4 		$690K Buy
193,874
+38,842
+25% +$179K ﹤0.01% 7856
2024
Q3 		$772K Buy
155,032
+78,213
+102% +$304K ﹤0.01% 7419
2024
Q2 		$200K Sell
76,819
-525,170
-87% -$1.75M ﹤0.01% 10360
2024
Q1 		$2.56M Buy
601,989
+563,732
+1,474% +$1.88M ﹤0.01% 4819
2023
Q4 		$77.3K Buy
38,257
+26,040
+213% +$46K ﹤0.01% 11501
2023
Q3 		$18.7K Sell
12,217
-80,982
-87% -$139K ﹤0.01% 11619
2023
Q2 		$154K Sell
93,199
-23,073
-20% -$41.7K ﹤0.01% 10554
2023
Q1 		$133K Buy
+116,272
New +$101K ﹤0.01% 11033
2022
Q4 		– Sell
-23,850
Closed -$28K – 12332
2022
Q3 		$28K Buy
+23,850
New +$27K ﹤0.01% 12468
2022
Q2 		– Sell
-48,511
Closed -$126K – 12818
2022
Q1 		$126K Sell
48,511
-118,928
-71% -$347K ﹤0.01% 11732
2021
Q4 		$651K Buy
167,439
+106,165
+173% +$533K ﹤0.01% 8447
2021
Q3 		$267K Sell
61,274
-39,036
-39% -$153K ﹤0.01% 10850
2021
Q2 		$398K Sell
100,310
-29,563
-23% -$118K ﹤0.01% 10147
2021
Q1 		$675K Buy
129,873
+66,699
+106% +$355K ﹤0.01% 8761
2020
Q4 		$338K Sell
63,174
-63,438
-50% -$380K ﹤0.01% 9035
2020
Q3 		$615K Buy
+126,612
New +$828K ﹤0.01% 7243
2020
Q2 		– Sell
-98,610
Closed -$454K – 10072
2020
Q1 		$216K Buy
98,610
+64,210
+187% +$244K ﹤0.01% 8550
2019
Q4 		$200K Buy
+34,400
New +$179K ﹤0.01% 8765

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Jeff Yass's AQST Position: Q2 2026 in Review

Jeff Yass reduced its Aquestive Therapeutics (AQST) stake by 62% in Q2 2026, selling an estimated $880K and leaving 128,505 shares worth $535K. The position accounts for ﹤0.01% of the portfolio, ranked #9768.

Jeff Yass first reported a position in AQST in Q4 2019 and has held it in 24 quarters since. The position peaked at $6.09M in Q3 2025. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Jeff Yass held 128,505 shares of Aquestive Therapeutics worth $535K as of Q2 2026.
  • Jeff Yass sold 209,130 Aquestive Therapeutics shares in Q2 2026, an estimated $880K.
  • Aquestive Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #9768 holding.
  • Jeff Yass first reported a position in Aquestive Therapeutics in Q4 2019 and has held it in 24 quarters since.
  • Jeff Yass's Aquestive Therapeutics position peaked at $6.09M in Q3 2025.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.